Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma



Status:Recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/31/2019
Start Date:June 26, 2017
End Date:May 29, 2021
Contact:Reference Study ID Number: NP39403 www.roche.com/about_roche/roche_worldwide.htm
Email:global-roche-genentech-trials@gene.com
Phone:888-662-6728 (U.S. Only)

Use our guide to learn which trials are right for you!

Open-label, Multicenter, Dose-escalation/Expansion Phase Ib Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients With Advanced Multiple Myeloma

This is a Phase Ib, open-label, multicenter, global study designed to assess the safety and
tolerability of RO6870810 as monotherapy and in combination with daratumumab in participants
with relapsed/refractory multiple myeloma. Each treatment cycle will be 21 days in length.
There are two parts to this study. A dose-escalation phase (Part I) will be used to evaluate
the safety and tolerability and dose limiting toxicities, and to establish the maximum
tolerated dose (MTR)/optimum biological dose (OBD) of RO6870810 when given as monotherapy or
in combination with daratumumab. A dose-expansion phase (Part II) will further characterize
the safety, tolerability and activity of RO6870810 as monotherapy or in combination with
daratumumab at the defined expansion dose-levels.


Inclusion Criteria:

- Performance status
- Life expectancy > 3 months

- Relapsed or refractory multiple myeloma. Participants with primary refractory myeloma
only allowed in dose-escalation phase of the study.

- Prior treatment: Treated with at least three prior lines of multiple myeloma therapy
including a proteasome inhibitor and an immuno modulatory agent or who are double
refractory to a proteasome inhibitor and an immuno modulatory agent. Prior anti-CD38
antibody (e.g., daratumumab, isatuximab) treatment is acceptable only for participants
receiving monotherapy treatment.

- Prior treatment: Treated with two or more lines of prior therapy, with disease
refractory to both a proteasome inhibitor and an immunomodulatory agent, and disease
progression (as defined by International Myeloma Working Group (IMWG) criteria)
following treatment with an anti-CD38 monoclonal antibody given as monotherapy or in
combination therapy. The most recent treatment regimen must have contained an
anti-CD38 monoclonal antibody.

- Treatment with prior autologous transplant is permitted

- Documented diagnosis of symptomatic multiple myeloma, as defined by the IMWG

- Measurable disease defined as at least one of the following: serum M-protein >/=1
grams/deciliter (g/dL), urine M-protein >/= 200 milligrams/24 hours (mg/24h), serum
free light chain (SFLC) assay: involved SFLCs >/= 10 mg/dL (>/= 100 mg/L) and an
abnormal SFLC ratio (<0.26 or >1.65).

- Female participants of childbearing potential must have a negative serum pregnancy
test within the 7 days prior to the first study drug administration.

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive methods that result in a failure rate
of < 1% per year during the treatment period and for at least 2 months after the last
dose of RO6870810 as monotherapy, or for at least 3 months after the last dose of
daratumumab.

- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures and agreement to refrain from donating sperm, as defined: With
female partners of childbearing potential or pregnant female partners, men must remain
abstinent or use a condom during the treatment period and for at least 4 months after
the last dose of RO6870810 as monotherapy, or for at least 3 months after the last
dose of daratumumab.

Exclusion Criteria:

- Plasma cell leukemia defined as peripheral plasma cell count > 2000/cubic millimeter
(mm^3)

- For expansion cohorts only: Primary refractory multiple myeloma defined as disease
that is non-responsive in participants who have never achieved a minimal response or
better with any therapy

- History of other malignancy within 2 years prior to screening, except for ductal
carcinoma in situ not requiring chemotherapy, appropriately treated carcinoma in situ
of the cervix, non-melanoma skin carcinoma, low-grade, localized prostate cancer
(Gleason score cancer

- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and
skin changes)

- Current or prior disease or treatment that could compromise protocol objectives in the
opinion of the Investigator and/or the Sponsor

- Pregnant or breastfeeding female.

- Consumption of agents which strongly inhibit CYP3A4 enzyme, within 7 days prior to the
first dose of study treatment and during the study.

- Consumption of agents which strongly induce CYP3A4 enzyme, within 14 days prior to the
first dose of study treatment and during the study.

- Surgery within 21 days prior to study entry.

- Prior treatment with small molecule BET family inhibitor or receiving steroids >the
equivalent of 10mg prednisone daily

- participants who are currently receiving any other investigational agent or have
received an investigational agent within 30 days or 5 half-lives, whichever is longer,
prior to study entry

- Uncontrolled cancer pain

- Prior anti-cancer therapy (chemotherapy, targeted agents, radiotherapy, and
immunotherapy) within 14 days except for alkylating agents (e.g., melphalan) within 28
days.
We found this trial at
10
sites
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
4201 Belfort Road
Jacksonville, Florida 32216
(408) 293-2336
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
1365 Clifton Road
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
2400 Pratt Street
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
1468 Madison Avenue
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Randwick, New South Wales
?
mi
from
Randwick,
Click here to add this to my saved trials